Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

828812

	registered interest
	date	23/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what his Department’s approach is to working with other departments on issues of intellectual property barriers to accessing affordable medicines.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	124440
	answer	answer is ministerial correction date of answer 29/01/2018 answer text <p>The Government recognises the vital role of intellectual property rights as an incentive and reward for research, development, and innovation. Organisations across Government, including the Department, Intellectual Property Office, NHS England, and the Medicines and Healthcare products Regulatory Authority, work together to support intellectual property rights holders while promoting best value treatment for National Health Service patients by ensuring a highly competitive environment for generic entrants where intellectual property rights have expired.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/01/2018 16:52:49 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

828820

	registered interest
	date	23/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lyme Disease: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer to Question 105278 on Lyme Disease: Vaccination, when he will publish the four systematic reviews commissioned by the Government into the evidence on Lyme Disease.
	tabling member constituency	Richmond Park
	tabling member printed	Zac Goldsmith
	uin	124447
	answer	answer is ministerial correction date of answer 29/01/2018 answer text <p>The Department has commissioned four independent systematic reviews of all relevant literature on the diagnosis, treatment, transmission and prevention of Lyme disease.</p><p> </p><p>The four systematic reviews have been completed and peer reviewed. The reviews were undertaken by the Evidence for Policy and Practice and Co-ordinating Centre and were published on its website on 21 December 2017. Patient advocacy groups involved in the review have been notified that these are in the public domain.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/01/2018 16:48:20 answering member 4067 label Biography information for Steve Brine
	tabling member	4062 label Biography information for Lord Goldsmith of Richmond Park

828803

	registered interest
	date	23/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medicine: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 13 November 2017 to Question 111610, on medicine: research, for what reasons it is not possible to assess the contribution made by public investment or private investment in bringing medicines to market.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	124433
	answer	answer is ministerial correction date of answer 29/01/2018 answer text <p>Many countries invest public funds in research and development (R&amp;D), often at an early stage. Some of this will contribute to basic science that will provide the fundamental knowledge and tools from which many different applications, including new medicines, may ultimately be developed. Some will be applied research related to a specific clinical application. Private companies also invest in R&amp;D, which may build on the results of both basic and applied research supported through public or private funding. Many potential medicines are taken part way through development but are not ultimately found to be suitable for clinical use, but this process provides an important part of the knowledge base that will go on to support future medicines development. Given all of these different factors that contribute to medicine development, it is not possible to assess the contribution made by public investment or private investment in bringing products to market.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/01/2018 16:53:57 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

828571

	registered interest
	date	23/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if his Department will take steps to introduce testing for all women over 30 years old for early signs of (a) ovarian and (b) breast cancer.
	tabling member constituency	Preston
	tabling member printed	Sir Mark Hendrick
	uin	124244
	answer	answer is ministerial correction date of answer 29/01/2018 answer text <p>The United Kingdom National Screening Committee (UK NSC) offers screening to an asymptomatic population for conditions which have been evaluated against their robust and extensive criteria. The UK NSC last reviewed the evidence to screen for ovarian cancer in 2016 and recommended that population screening should not be offered. Research has shown that screening women under the age of 50 is less effective especially when they have not entered into the menopause phase.</p><p> </p><p>There are currently no plans to offer screening to women over the age of 30 for either ovarian or breast cancer.</p><p> </p><p>A proposal to change an existing programme, such as age to the breast screening programme would follow the UK NSC’s evidence review process. Information about this process is available at:</p><p> </p><p><a href="https://www.gov.uk/government/publications/uk-nsc-evidence-review-process" target="_blank">https://www.gov.uk/government/publications/uk-nsc-evidence-review-process</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/01/2018 17:00:31 answering member 4067 label Biography information for Steve Brine
	tabling member	473 label Biography information for Sir Mark Hendrick